Format

Send to

Choose Destination
Eur J Cancer. 2016 Nov;67:213-222. doi: 10.1016/j.ejca.2016.07.024. Epub 2016 Sep 28.

Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.

Author information

1
Integrated Mathematical Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Eunjung.Kim@moffitt.org.
2
The Department of Tumor Biology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
3
Integrated Mathematical Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Abstract

BACKGROUND:

One of major issues in clinical trials in oncology is their high failure rate, despite the fact that the trials were designed based on the data from successful equivalent preclinical studies. This is in part due to the intrinsic homogeneity of preclinical model systems and the contrasting heterogeneity of actual patient responses.

METHODS:

We present a mathematical model-driven framework, phase i (virtual/imaginary) trials, that integrates the heterogeneity of actual patient responses and preclinical studies through a cohort of virtual patients. The framework includes an experimentally calibrated mathematical model, a cohort of heterogeneous virtual patients, an assessment of stratification factors, and treatment optimisation. We show the detailed process through the lens of melanoma combination therapy (chemotherapy and an AKT inhibitor), using both preclinical and clinical data.

RESULTS:

The mathematical model predicts melanoma treatment response and resistance to mono and combination therapies and was calibrated and then validated with in vitro experimental data. The validated model and a genetic algorithm were used to generate virtual patients whose tumour volume responses to the combination therapy matched statistically the actual heterogeneous patient responses in the clinical trial. Analyses on simulated cohorts revealed key model parameters such as a tumour volume doubling rate and a therapy-induced phenotypic switch rate that may have clinical correlates. Finally, our approach predicts optimal AKT inhibitor scheduling suggesting more effective but less toxic treatment strategies.

CONCLUSION:

Our proposed computational framework to implement phase i trials in cancer can readily capture observed heterogeneous clinical outcomes and predict patient survival. Importantly, phase i trials can be used to optimise future clinical trial design.

KEYWORDS:

Clinical trials; Heterogeneity of patient responses; Mathematical model; Stratification; Treatment schedule optimisation

PMID:
27689717
PMCID:
PMC5658204
DOI:
10.1016/j.ejca.2016.07.024
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center